Cargando…
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is a recently emerged respiratory coronavirus that has infected >23 million people worldwide with >800,000 deaths. Few COVID-19 therapeutics are available, and the basis for severe i...
Autores principales: | Busnadiego, Idoia, Fernbach, Sonja, Pohl, Marie O., Karakus, Umut, Huber, Michael, Trkola, Alexandra, Stertz, Silke, Hale, Benjamin G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484541/ https://www.ncbi.nlm.nih.gov/pubmed/32913009 http://dx.doi.org/10.1128/mBio.01928-20 |
Ejemplares similares
-
Restriction factor screening identifies RABGAP1L-mediated disruption of endocytosis as a host antiviral defense
por: Fernbach, Sonja, et al.
Publicado: (2022) -
SARS-CoV-2 variants reveal features critical for replication in primary human cells
por: Pohl, Marie O., et al.
Publicado: (2021) -
Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir
por: Pohl, Marie O., et al.
Publicado: (2021) -
Interferon system deficiencies exacerbating severe pandemic virus infections
por: Stertz, Silke, et al.
Publicado: (2021) -
BRD9 is a druggable component of interferon‐stimulated gene expression and antiviral activity
por: Börold, Jacob, et al.
Publicado: (2021)